RE:RE:RE:RE:RE:Quote from Keytruda.com
Most of the world has no awareness of a tiny CDA venture stock using a non-immunotherapy approach. As such, it is not on any radar. This makes financing really hard.
All of the competing agents out there are immune therapy ones which suggests that they are stuck in one track mode. That means TLT could be in a good place to disrupt things. Just needs money to do so.
CV oncology had an insane number of study sites around the works so recruiting was easier. You could argue that the overall recruitement success rate per site was low though....